37 filings · most recent first
ROIV 8-K Filings
Roivant Sciences Ltd Shareholders Approve Key Proposals At Annual Meeting
Roivant Announces Positive Phase 2 Results For Mosliciguat In Phild
Roivant Sciences Reports Q1 2026 Financial Results And Business Update
Roivant Sciences Announces 225 Billion Settlement With Moderna And Reports Q4
Roivant Announces Positive Phase 2 Results For Brepocitinib In Cutaneous
Roivant Sciences Lisraya Approved By Fda For Dermatomyositis Treatment
Roivant Sciences Announces Fda Approval Of Lisraya For Dermatomyositis
Roivant Announces New Phase 2B3 Trial For Brepocitinib In Lichen Planopilaris
Roivant Sciences Ltd Resolves Patent Litigation With Moderna
Roivant Announces 225 Billion Settlement With Moderna And New Share Repurchase
Roivants Priovant Receives Fda Priority Review For Brepocitinib In
Roivant Sciences Hosts Investor Day With Key Pipeline Updates
Roivant Reports Second Quarter 2025 Financial Results And Business Update
Roivant Announces Positive Phase 3 Results For Brepocitinib In Dermatomyositis
Roivant Sciences Ltd Shareholders Approve All Proposals At 2025 Agm
Roivant Announces Sixmonth Remission Data For Graves Disease Therapy
Roivant Reports Q1 2025 Financial Results And Provides Business Update
Roivant Sciences Ltd Announces New 500 Million Share Repurchase Program
Roivant Reports Fiscal 2025 Results And Business Update
Immunovant Leadership Changes And New Imvt1402 Indications Announced
Roivant Sciences Ltd Announces Consulting Agreement With Former Cao
Roivant Announces Positive Results For Batoclimab In Mg And Cidp Studies
Roivant Sciences Ltd Appoints New Principal Accounting Officer
Roivant Reports Third Quarter 2024 Financial Results And Business Update
Roivant Sciences Announces Topline Results From Phase 2 Resolvelung Study Of
Roivant Reports Q2 Financial Results And Business Updates
Organon Completes Acquisition Of Dermavant
Roivant Sciences Announces Merger Agreement With Organon
Roivant Sciences Announces Dermavant Acquisition By Organon
Roivant Sciences Ltd Announces 2024 Annual Shareholder Meeting Results
Roivant Announces New Pipeline Program Mosliciguat For Phild
Roivant Provides Positive Update On Graves Disease Treatment
Roivant Reports Q1 2024 Financial Results And Business Update
Dermavant Sciences Ltd Renegotiates Debt Obligations Reducing Future Cash
Roivant Reports Q4 And Fy 2024 Results Authorizes 15B Share Repurchase
Roivant Announces Positive Study Results And Authorizes 15B Share Repurchase
Roivant Announces Strong Q3 2023 Results With Substantial Gain From Telavant